DelSiTech at-a-Glance
DelSiTech is a technology platform company specializing in long-acting formulations, dedicated to transforming the treatment landscape in the areas of metabolic disease and pain through our lead long-acting injectable assets.
DelSiTech’s proprietary Silica Matrix technology platform is highly versatile and has demonstrated compatibility with a wide range of therapeutic agents, including small molecules, peptides, and large biologics. The product can be formulated to release drug over days, weeks, or even months, providing patients and caregivers with possible access to long-lasting treatment options.
DelSiTech believes in collaboration. Our global partner network spans the biopharmaceutical and pharmaceutical industries, and we remain dedicated to working together to advance ultra long-acting drug delivery solutions through our Silica Matrix technology.
Our Goals:
DelSiTech aims to deliver new therapeutic products that offer better patient adherence and reduced dosing frequency through long-acting injectables, with the potential to support improved therapeutic outcomes.
Our strategy is defined by these three pillars:
- Developing our pipeline of proprietary in-house long-acting injectable drug products.
- Partnering with and licensing our proprietary slow-releasing Silica Matrix drug delivery technology to biopharmaceutical and pharmaceutical partner companies.
- Continuing to develop our technology and patent portfolio and explore new opportunities for novel products.
Aligned with our strategic focus, DelSiTech’s purpose is to improve patients’ quality of life through long-acting drug delivery solutions. As an additional benefit of fewer doses, our natural Silica Matrix platform also supports sustainability by helping to reduce medical waste — including waste that might otherwise end up in the environment.